Slide 1: Meet AZN management: ASCO 2019 Breakout 4: trastuzumab deruxtecan
Marquis_CONFERENCE AZ2019 Meet AZN management: ASCO 2019 Breakout 4: trastuzumab deruxtecan José Baselga, Executive Vice President, Oncology R&D 3 June 2019
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, pe
Slide 3: Trastuzumab deruxtecan: a state-of-the-art HER2-targeted, second-generation ADC
Trastuzumab deruxtecan A state-of-the-art HER21-targeted, second-generation ADC2 Differentiated ADC • Higher-intensity chemotherapy (more payload on each antibody) • Membrane permeability (potential HER2-low applicability) • Selective protease-cleavable linker • Short half-life of free payload reduc
Slide 4: Unprecedented Phase I/II data
Trastuzumab deruxtecan Unprecedented Phase I/II data Differentiated ADC Phase II primary endpoint met 59.5% confirmed objective response rate 93.7% confirmed disease control rate1 20.7months median duration of response2 Progression-free survival Unprecedented data in advanced Phase II trial met prim
Slide 5: Trastuzumab deruxtecan in breast cancer and beyond
Trastuzumab deruxtecan in breast cancer and beyond Opportunities across treatment settings in breast cancer Neo-adjuvant / adjuvant 1st-line metastatic 2nd-line metastatic 3rd-line metastatic Post neo-adjuvant Replace Replace HER2-positive trastuzumab chemotherapy + Replace Post emtansine breast can
Slide 6: Encouraging efficacy in HER2-low breast cancer
Trastuzumab deruxtecan Encouraging efficacy in HER2-low breast cancer HER2-low breast cancer efficacy Percentage change in tumour size from baseline (%) Best percentage change in tumour size from baseline (%) 44.2% objective response rate 9.4 months DoR2, 7.6 months median PFS3 HR: hormone receptor.
Slide 7: Compelling efficacy in other cancer types
Trastuzumab deruxtecan Compelling efficacy in other cancer types HER2-positive gastric cancer HER2-positive and HER2-mutated NSCLC N=44 N=11 HER2mut Three average lines of prior treatment 43% ORR 73% ORR1 5.6 months median PFS 14.1 months median PFS1 Source: abstract #13325, Tsurutani et al, WCLC 20
Slide 8: Development plans and news flow
Trastuzumab deruxtecan Development plans and news flow Extensive Phase II/III programme underway News flow • US FDA BTD2 granted in Aug 2017 2L DESTINY- Breast03 • DESTINY-Breast01 data (2020+) presentation in H2 2019 3L+ DESTINY- • Regulatory decision anticipated in Breast02 (2020+) 2020 To be comm
Slide 9: Q&A
Q&A
Slide 10: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non- commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availab